Irie Biotechnology Co., Ltd.

As a biotech startup company registered in Taiwan, and on our way to market, it's our mission to contribute a novel and unique solution to the 21st Century healthcare sector. Globally, health epidemics such as the Metabolic and Neurodegenerative Diseases, Cancer and many others, are on a steady rise. Medical interventions from pharmaceutical segment, do not work for the population. All technological advancements of the past decades, appear unable to slow down surging prevalence of these diseases, let alone offer problem-solving or preventive solutions. The inhumane healthcare business mantra “A Patient Cured is a Customer Lost” seems ever more prevalent, and safe effective solutions are direly needed. At Irie Biotech, we have developed a unique and economically superior way, to mass-produce the naturally occurring Metallothionein (MT) proteins, with all their outstanding functions preserved. MTs are among Nature’s most powerful weapons for attenuating, and preventing onset of most contemporary lifestyle diseases. Validated functions include promotion of longevity, and MTs are proven bioavailable via oral and topical routes. Based on decades of academic research, from a global science community, MTs are overdue to reach market, and are poised to have genuine impact on society and people’s health and wellbeing. With product and process R&D concluded, our remaining steps to market need to be financed. Our off-beat approach might lack virtually all buzzwords upon which the 21st Century startup world operates. However and nonetheless, the unrivaled product-market-fit of MTs, economically mass-produced with a proprietary technology, as well as an ever-growing global market, are our fail-safe stepping stones to success. We are confident that our approach matches beautifully the needs of investors and business partners focused on long-term value-generation, as well as those of all value-demanding customers.